About us

Enara Bio™ (formerly known as Ervaxx) is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. We were founded as Ervaxx Ltd in late 2016 with an initial focus on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-related DNA sequences.

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are exploring the hidden depths of cancer and T-cell biology to discover and characterize unconventional immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from the altered cellular processes in cancer cells.

Enara Bio is backed by leading life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with a number of world class academic institutions including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive our differentiated science.

Enara Bio Our Story Poster

Management Team

Board of Directors

Scientific Advisory Board

Adrian Hill, MB BCh DPhil University of Oxford, Oxford, UK. Find out more Sadik Kassim PhD CTO, Danaher Corporation Find out more George Kassiotis, PhD Co-founder. Francis Crick Institute, London, UK. Find out more Mike Quigley, PhD Senior Vice President, Gilead Find out more Drew Pardoll, MD PhD Co-founder. Johns Hopkins University, Baltimore, USA. Find out more Andrew Sewell, PhD Cardiff University, Cardiff, UK. Find out more Nicola Ternette, PhD University of Oxford, Oxford, UK. Find out more Eliezer Van Allen, MD PhD Dana-Farber Cancer Institute, Boston, USA. Find out more